$5.10+0.16 (+3.24%)
At close: Nov 16, 2026, 9:44 AM ET· Nasdaq · USD
Regencell Bioscience Holdings (RGC) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
Business enginePre-revenue: no positive revenue in any year through FY26, so the growth and margin read is withheld. Worth your attention in FY26: Returns vs FCF (n/m). Visible in the receipts below.
The lines that matter · FY22–FY26
Revenue ($M)—
0.0
FY22→FY26CAGR —
Net income ($M)▼226.5%
−11.7
FY22→FY26CAGR —
Free cash flow ($M)▼135.6%
−7.7
FY22→FY26CAGR —
What the receipts whisper · what a headline number hides
Share count
+1.6%
486.6mn → 494.6mn diluted shares since FY22. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$0.0K
−100.0% YoY in FY26.
Returns vs FCF
n/m
$1.8M returned vs $−7.7M of FCF in FY26. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY22–FY26 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY26 † | FY26 | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→26 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 1,299.6 | 1,299.6 | 948.3 | 1,066.2 | 1,581.6 | 2,512.2 | ▲37.0% | −15.2% |
Selling, general & admin | 10,418.3 | 10,418.3 | 2,813.7 | 3,545.1 | 4,429.4 | 5,080.3 | ▲270.3% | +19.7% |
Total operating expenses | 11,724.5 | 11,724.5 | 3,770.0 | 4,736.7 | 6,273.7 | 7,617.8 | ▲211.0% | +11.4% |
Operating incomefeeds ROC rank | −11,724.5 | −11,724.5 | −3,770.0 | −4,736.7 | −6,273.7 | −7,617.8 | ▼211.0% | — |
Other income, net | 22.5 | 22.5 | 185.8 | 373.5 | 211.3 | 23.2 | — | — |
Pretax income | −11,701.9 | −11,701.9 | −3,584.2 | −4,363.2 | −6,062.3 | −7,594.6 | ▼226.5% | — |
Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −11,701.9 | −11,701.9 | −3,584.2 | −4,363.2 | −6,062.3 | −7,594.6 | ▼226.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | —A | —A | —A | —A | —A | — | — |
Diluted shares (mn) | 494.60 | 494.60 | 494.49 | 494.49 | 494.49 | 486.62 | ▲0.0% | +0.4% |
| Margins | ||||||||
† FY26 = fiscal 2026, through 2026-06-30; the trailing year is not available.A Withheld by our checks.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-10-07 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

